

**Do you want
to stop his pain...
..or heal his ulcer?**

Why not do both at once?

DUOGASTRONE[®]




BIOGASTRONE[®]



Full details available on request

J.3572

The graph below compares mortality rates due to faecal peritonitis, era by era. It is not pedantically accurate because its sources differ. But the point is fairly made.



Why inaccurate? Because column 4 refers to 23 cases of faecal peritonitis which were treated successfully with Noxyflex. But the *3 deaths which occurred were due to causes other than peritonitis - as post-mortem revealed. **The mortality rate due to peritonitis can therefore be regarded as zero.**

* The whole graph, and the causes of the deaths referred to are the subject of the new Noxyflex folder "Why three deaths?" You will receive at least one copy!

**When bacterial contamination
of the peritoneum is
diagnosed or suspected:**

Noxyflex
Geistlich Chester

CAVED-S

Important Notice re: Duodenal Ulcers

The reason for the failure of chemotherapy in the treatment of duodenal ulcers may well be due to underdosage. The dosage that the condition and recurrent episodes may demand of antacids, anticholinergics, carbenoxolone or sedatives is such that the resultant side effects cannot be tolerated. Whereas the standard dose for gastric ulcers may not always be effective with duodenal ulcers.¹

It has now been established that Caved-S tablets prescribed in doses related to the condition of duodenal ulcer patients, can result in successful long term, safe and acceptable treatment with patients who have not responded to many other forms of therapy.

A metabolic study² and more than twenty hospital trials, and treatment with more than eight million patients in over forty countries has proven Caved-S deglycyrrhizinated liquorice is free from side effects of oedema, hypokalaemia etc.^{3, 4}

An unpublished hospital trial, the results of which are in our hands, has been carried out with Caved-S tablets at increased dosage on forty severe duodenal ulcer patients (age range 40-65) who had all been referred for surgery has demonstrated recurrent episodes can be prevented. The report stated "Patients with severe duodenal ulcers who had been referred for surgery were divided into two groups and treated with either eight or twelve tablets daily, for eight or sixteen weeks respectively.

The higher dosage was statistically more effective than the lower dosage in preventing relapses . . ." Patients were followed up for a minimum of one year and it was concluded that,

"HIGH DOSES OF DEGLYCYRRHIZINATED LIQUORICE (CAVED-S) SHOULD BE GIVEN TO PATIENTS WITH DUODENAL ULCERS BEFORE SURGERY IS ATTEMPTED".

CAVED-S 
the ulcer fighter

References

- (1) GUT 12: 449-451 (1971)
- (2) Digestion 4: 264-268 (1971)
- (3) B.M.J. 1: 154-160 (1970)
- (4) GUT 10: 299-302 (1969)

Information available from:
Tillotts Laboratories, 44 Lupus Street, London SW1. 01-828 3641

Your patient
has to live with
the suture...

PROLENE*
Polypropylene
Sutures

inert as steel

ETHICON, LTD. SCOTLAND

*Trademark © ETHICON Ltd 1972

duphalac[®] in lactulose liver failure

Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut describes its role in these terms.*

“Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .
. . . lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required”. *Gut, 1970, 11: 1043-1048

The following work on Duphalac in portal systemic encephalopathy has been published:

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1: 890-892.

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2: 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2: 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76: 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11: 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281: 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18: 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose *Therapeutische Umschau und medizinische Bibliographie*, 1969, 26: 275-277

Lactulose treatment of chronic hepatoportal encephalopathy: a clinical and electroencephalographic study *Acta medica Scandinavica*, 1970, 187: 337-346

The value of EEG frequency analysis in hepatic encephalopathy *J. Ryl. Coll. Surg. Edinb.*, 1970, 15: 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy *Quarterly Journal of Medicine*, 1970, 39: 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy *Gastroenterology*, 1970, 59: 827-832

Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.

Further information available on request.


duphar DUPHAR LABORATORIES LIMITED BASINGSTOKE HANTS. TEL 0256 26351
PHILIPS-DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271



ARCHIVES FRANÇAISES DES MALADIES DE L'APPAREIL DIGESTIF

**The most important French
periodical on the subject**

*Organe Officiel de la Société
Nationale Française de Gastro-
Entérologie et de ses filiales*



Publishing all articles concerning the work of physicians, surgeons, electro-radiologists and biologists which are relevant to Gastro-enterology.

Starting in 1968, the "Archives Françaises des maladies de l'appareil digestif" — publish four numbers a year entitled "Biologie et Gastroentérologie" devoted to reports on experimental work in gastro-enterology carried out in the new research units of the various French University Hospital Centres.

These articles are original works, clinical, radiological, biological and anatomy-pathological papers (with illustrations and bibliography).

The articles are written in French and followed by a summary in French and English.

The Archives also publish summaries of the Proceedings of the Societies of which they are the

official organ, the texts of conferences or communications which are presented to them, Proceedings of Congresses or Colloquia, book and journal reviews.

The Archives publish announcements of national and international meetings on all subjects concerned with Gastro-enterology.

SOME ARTICLES RECENTLY PUBLISHED

Effect of intestinal transit time assessed by the action of carminochrome on the composition of the stools by M. SMADJA and J. J. BERNIER

Gastric polyps. Polyposis and chronic gastritis by A. CORNET, P. RENAULT, F. CARNOT, D. BLANC, PH. DELAVIERRE and G. TERRIS

Catheterisation of the Vater ampulla during duodenoscopic examinations. Techniques and results by R. JEANPIERRE, J. LAURENT, M. BAS, J. FAYS, R. DORNIER, M. BIGARD, F. VICARI, P. GAUCHER and F. HEULLY

The indirect immunofluorescent reaction in amebiasis Report of 150 cases by A. MOLINIER, G. MIMOUNE and Mlle. A. SUPIOT

Giant extra-gastric cystic schwannoma. Diagnostic difficulties (An observation) by J. RAUTUREAU, G. GROSS, J.-P. CLOT and G. CHOMETTE

A case of internal diverticulum of the duodenum. One case by NGUYEN DINH HOANG and NGUYEN THANH LAN

Serial radioimmunoassay of serum gastrin in a case of Zollinger-Ellison syndrome by J.-C. CROISIER, M. HUGUIER and Mlle. G. CROISIER

Subscription (11 numbers) 1972. France F.155. Other countries F.215.

Specimen copy available on application to:

MASSON & CIE — Editeurs. 120 Boulevard Saint Germain, 75 - PARIS 6°